CD146 Antibodies: Targeting Lipid Metabolism and Energy Homeostasis to Intervene in Obesity

CD146 Antibodies: Targeting Lipid Metabolism and Energy Homeostasis to Intervene in Obesity – Presented by ANT BIO PTE. LTD.

1. Concept
CD146 (melanoma cell adhesion molecule, MCAM) is a cell surface adhesion molecule with low expression in most normal adult tissues but significantly elevated levels in adipose tissue. This tissue-specific expression pattern highlights its unique role in adipose biology and metabolic regulation. Notably, CD146 expression in adipose tissue is further upregulated in obese individuals and animal models (high-fat diet-induced, age-related, genetically obese), showing a positive correlation with obesity severity. As a functional receptor for angiopoietin-like protein 2 (ANGPTL2) and galectin-1, CD146 regulates adipocyte differentiation, lipid metabolism, and energy expenditure—making it a key target for obesity research and intervention. CD146 antibodies, developed by ANT BIO PTE. LTD., enable precise detection and functional modulation of this molecule, supporting advances in metabolic disease research.

2. Research Frontiers
Cutting-edge research on CD146 has uncovered its multifaceted role in obesity and metabolic regulation, driving innovations in therapeutic development:
Adipocyte Differentiation Regulation: CD146 promotes white adipocyte differentiation via activating the cAMP response element-binding protein (CREB) signaling pathway. Adipocyte-specific CD146 knockout inhibits white adipose tissue accumulation, improves insulin sensitivity, and alleviates chronic inflammation—validating its pro-obesity role.
Lipid Metabolism Modulation: In mature white adipocytes, CD146 signaling upregulates lipid synthesis-related genes and suppresses fatty acid oxidation, exacerbating lipid storage and metabolic imbalance. It also regulates inflammatory factor secretion, contributing to obesity-associated chronic inflammation.
Energy Homeostasis Control: In brown adipose tissue, CD146 binds galectin-1 to suppress uncoupling protein 1 (UCP1) expression, reducing thermogenic activity and energy expenditure—providing a molecular explanation for reduced energy metabolism in obesity.
Therapeutic Potential of Antibodies: CD146-targeted monoclonal antibodies block ligand-receptor interactions, exerting anti-obesity effects in preclinical models. They inhibit white adipose tissue hyperplasia and lipid accumulation, while enhancing brown adipose tissue thermogenesis—additionally improving insulin sensitivity, alleviating fatty liver, and reducing chronic inflammation.

3. Research Significance
CD146 research holds profound implications for understanding obesity pathogenesis and developing novel therapeutics:
Mechanistic Insights: It reveals the molecular links between cell adhesion molecules, adipocyte biology, and metabolic balance, expanding knowledge of obesity’s complex regulatory networks.
Therapeutic Target Validation: CD146’s tissue-specific expression in adipose tissue and multi-pathway regulation of obesity make it a safe and effective target for drug development.
Comprehensive Metabolic Improvement: CD146 antibody therapy addresses both obesity and its complications (insulin resistance, fatty liver, chronic inflammation), offering a holistic approach to metabolic syndrome management.
Translational Value: Preclinical success lays the groundwork for clinical trials, with potential to fill the unmet need for targeted anti-obesity drugs.

4. Related Mechanisms, Research Methods, and Product Applications
Related Mechanisms
CD146 regulates obesity through tissue-specific and ligand-dependent mechanisms:
White Adipose Tissue: Binds ANGPTL2 to activate CREB signaling, promoting adipocyte differentiation, lipid synthesis, and inflammatory factor secretion.
Brown Adipose Tissue: Interacts with galectin-1 to downregulate UCP1, inhibiting thermogenesis and energy expenditure.
Signaling Cascades: CD146-mediated signaling involves pathways such as Akt, ERK, and NF-κB, which modulate adipocyte function and metabolic gene expression.

Research Methods
CD146 antibodies support core research techniques in metabolic biology:
Expression Analysis: Flow cytometry and immunohistochemistry to detect CD146 expression in adipose tissue and adipocyte subsets.
Functional Assays: Adipocyte differentiation assays, lipid synthesis/oxidation measurements, and thermogenesis (UCP1 expression) analysis.
Signaling Pathway Studies: Western blot and co-immunoprecipitation to investigate CD146-interacting proteins and downstream signaling cascades.
In Vivo Studies: Evaluation of anti-obesity efficacy and metabolic improvement in obese animal models treated with CD146 antibodies.

Product Applications by ANT BIO PTE. LTD.
ANT BIO PTE. LTD., via its sub-brand STARTER (specializing in high-performance antibodies), offers a curated portfolio of CD146 antibodies with exceptional specificity, affinity, and batch consistency. These products are validated for flow cytometry, immunohistochemistry, and functional assays, enabling diverse research applications:
Obesity and Metabolic Research: Study CD146’s role in adipocyte differentiation, lipid metabolism, and energy homeostasis.
Angiogenesis Studies: Detect CD146 expression in tumor or retinal blood vessels to assess angiogenesis status.
Tumor Metastasis Research: Explore CD146’s function in epithelial-mesenchymal transition and metastasis of melanoma, prostate cancer, etc.
Immunology and Stem Cell Research: Identify CD146-positive T cell subsets or stem cell populations (e.g., mesenchymal stem cells) for functional analysis.

5. Brand Mission
At ANT BIO PTE. LTD., our mission is to empower global innovative pharmaceutical companies, research institutions, and life science researchers with high-quality, high-value biological reagents and comprehensive solutions. Leveraging state-of-the-art technology platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development systems (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—we strive to accelerate scientific discovery and translational research. Our sub-brands (Absin for general reagents and kits, STARTER for antibodies, and UA for recombinant proteins) synergize to address diverse research needs, contributing to breakthroughs in metabolic diseases, oncology, and vascular biology. With certifications including EU 98/79/EC, ISO9001, and ISO13485, we uphold the highest standards of quality and reliability to support our mission of advancing human health through science.

6. Related Product List

S0B8420	Mouse Anti-Human CD146 Antibody (S-3679)	Host : Mouse Conjugation : Unconjugated
S0B8417	FITC Mouse Anti-Human CD146 Antibody (S-3679)	Host : Mouse Conjugation : FITC
S0B8413	Biotin Mouse Anti-Human CD146 Antibody (S-3679)	Host : Mouse Conjugation : Biotin
S0B8259	Alexa Fluor® 647 Rat Anti-Mouse CD146 Antibody (S-R606)	Host : Rat Conjugation : Alexa Fluor® 647
S0B8187	Alexa Fluor® 488 Rat Anti-Mouse CD146 Antibody (S-R606)	Conjugation : Alexa Fluor® 488
S0B5701	FITC Rat Anti-Mouse CD146 Antibody (S-R606)	Host : Rat Conjugation : FITC

7. AI Disclaimer
This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.
 
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.